EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Oct 22, 2026
Excerpt: 10 signals (from 47 total). Healthcare leads (18). price range $15-$268. 2 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
The sharp divergence between major indices on October 22nd tells an important story: technology-heavy growth names are under meaningful pressure (Nasdaq -2.60%) while value-oriented, defensive positioning is holding firm (Dow essentially flat). This split risk appetite creates a nuanced environment for dip-bounce reclaim strategies, where the quality of the bounce matters more than the magnitude of the dip. Traders should expect wider intraday price ranges and less predictable follow-through, as participants are selectively rotating rather than broadly selling or buying.
The VIX surge of over 14% to 19.03 is the most critical factor for these 47 signals. Elevated volatility expands the natural price swings that dip-bounce setups rely on, which can accelerate gains when a reclaim confirms — but it equally increases the risk of false reclaims and whipsaw action. At 19.03, the VIX is approaching territory where options premiums become notably more expensive, meaning protective hedges cost more and stop-loss levels need to be wider to avoid being shaken out by noise. Discipline around entry timing and confirmation is essential in this environment.
Healthcare's emergence as the top sector for signals aligns well with the current defensive rotation visible in the Dow's relative outperformance. Healthcare tends to attract capital during periods of growth uncertainty, giving dip-bounce setups in this sector a potential tailwind from genuine sector rotation rather than speculative momentum. This structural support improves the probability profile for reclaim signals here compared to sectors still absorbing selling pressure, though the elevated VIX remains a reminder that even defensive plays carry elevated short-term risk.
📊 Signals (10 of 47 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|---|
| 1 | BHVN | Biohaven Ltd. | Healthcare | $14.69 | 0.22 | — | — | $2.2B |
| 2 | FITB | Fifth Third Bancorp | Financial Services | $53.23 | 0.21 | — | 0d | $48.3B |
| 3 | TNGX | Tango Therapeutics, Inc. | Healthcare | $27.93 | 0.20 | — | — | $4.7B |
| 4 | BMY | Bristol-Myers Squibb C... | Healthcare | $63.00 | 0.19 | — | 7d | $128.7B |
| 5 | MMM | 3M Company | Industrials | $175.54 | 0.19 | — | — | $90.5B |
| 6 | ROIV | Roivant Sciences Ltd. | Healthcare | $37.45 | 0.19 | — | — | $27.1B |
| 7 | IRON | Disc Medicine, Inc. | Healthcare | $75.03 | 0.19 | Sell -$34,935 | — | $2.9B |
| 8 | AGIO | Agios Pharmaceuticals,... | Healthcare | $37.19 | 0.19 | — | — | $2.2B |
| 9 | JNJ | Johnson & Johnson | Healthcare | $267.61 | 0.18 | — | — | $644.9B |
| 10 | WFG | West Fraser Timber Co.... | Basic Materials | $69.68 | 0.16 | — | — | $5.3B |
Recent Headlines
BMY (Bristol-Myers Squibb Company)
- A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Value $56.81 vs Price $63.00
- Bristol Myers Squibb vs. Pfizer: Consistency vs.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.